154 filings
Page 3 of 8
8-K
vfx8o
16 May 22
Company preparing for Q4 commercial launch, if approved
7:14am
DEFA14A
agsq2
28 Apr 22
Additional proxy soliciting materials
4:02pm
8-K
q7bykg5y
11 Apr 22
Anticipates Q4 2022 commercial launch, if approved
7:44pm
S-8
wucwly wyuq5a3
22 Mar 22
Registration of securities for employees
4:08pm
8-K
wszvav7st7hla6dm8j72
22 Mar 22
Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved
7:11am
8-K
ro9fyi p5evakm1g
9 Nov 21
All additional testing of devices manufactured on the planned commercial line, as required by the FDA, has been successful to date
7:09am
8-K
yqtx 9o2r397ddz83933
10 Sep 21
Heart Failure Society of America Annual Scientific Meeting 2021
8:12am
8-K
78zrr0pth 2m
11 Aug 21
Announced positive top-line results from the FREEDOM-HF study demonstrating that average 30-day heart failure-related costs
7:07am
8-K
bvr96m
14 Jul 21
Other Events
12:00am
8-K
0slmg
1 Jul 21
FDA and Company in alignment on the path forward
8:10am
8-K
b8t sgugv0
9 Jun 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
pln0sm4p jgb2g
12 May 21
FREEDOM clinical study on track for topline results in Q3 2021
8:06am
EFFECT
kuzwi
30 Apr 21
Notice of effectiveness
12:15am
DEFA14A
swxd9v5a
27 Apr 21
Additional proxy soliciting materials
4:02pm